Skip to content
drillr.ai
Sign up

TAK

Takeda Pharmaceutical Company Limited

NYSE · Healthcare · Drug Manufacturers - Specialty & Generic · JP

Also listed · 4502.T →
$19.61
−0.31%
Ask drillr

  • Aug 6, 2026, 02:20 UTC

    Veritas In Silico ended its joint research collaboration with Takeda Pharmaceutical Company in April 2026 after achieving certain results and mutual discussions.

    Source:

  • Jul 30, 2026, 20:01 UTC

    Keros Therapeutics will receive a $20 million development milestone payment from Takeda after the first patient was dosed in the ELRiSE MDS clinical trial.

    Source:

  • Jul 30, 2026, 06:30 UTC

    Takeda Pharmaceutical reported its fiscal Q1 (April-June 2026) consolidated net profit of 113.1 billion yen, down 8.9% year-on-year.

    Source:

  • Jul 28, 2026, 09:59 UTC

    Alembic Pharmaceuticals received final USFDA approval to market Prucalopride Tablets in 1 mg and 2 mg strengths in the United States.

    Source:

  • Jul 17, 2026, 17:08 UTC

    Takeda Pharmaceutical Co. Ltd. announced encouraging secondary data from two pivotal Phase 3 trials of its oral psoriasis drug zasocitinib.

    Source:

  • Jul 15, 2026, 18:59 UTC

    Insilico Medicine and Takeda Pharmaceutical signed a global strategic collaboration agreement with a total potential value of up to $600 million.

    Source:

  • Jul 13, 2026, 08:18 UTC

    Takeda Pharmaceutical announced on July 13, 2026 that it will open up to four plasma donation centers in Indonesia by 2027, with an initial investment of up to $30 million, marking its first such facility in ASEAN.

    Source:

  • Jul 13, 2026, 03:50 UTC

    Takeda Pharmaceutical Company Limited and the Indonesian Government announced a landmark collaboration to strengthen healthcare resilience and expand access to plasma-derived medicinal products, marked by a fractionation license granted to Takeda.

    Source:

  • Jul 2, 2026, 00:29 UTC

    Insilico Medicine entered into a strategic collaboration with Takeda Pharmaceutical to discover AI-powered drug candidates, with total potential value up to $600 million.

    Source:

  • Jun 11, 2026, 11:03 UTC

    Takeda Pharmaceutical announced that its experimental once-daily psoriasis pill outperformed Bristol Myers Squibb's Sotyktu in a late-stage head-to-head trial.

    Source:

  • Jun 5, 2026, 07:54 UTC

    Takeda Pharmaceutical recorded a $2.52 billion provision for antitrust litigation related to its constipation drug Amitiza, resulting in a net loss for the fiscal year ended March.

    Source:
← PreviousPage 2